148038-83-9

Basic information

• Product Name: 2H-Imidazo[4,5-b]pyridin-2-one,6-bromo-1,3-dihydro-
• Synonyms: 6-Bromo-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one;6-Bromo-1,3-dihydroimidazo[4,5-b]pyridin-2-one
• CAS NO: 148038-83-9
• Molecular Formula: C₆H₄BrN₃O
• Molecular Weight: 214.0195
• Mol File: 148038-83-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: >350°
• Boiling Point: 189.4 °C at 760 mmHg
• Flash Point: 68.4 °C
• Appearance: /
• Density: 1.837 g/cm³
• Vapor Pressure: 0.57mmHg at 25°C
• Refractive Index: 1.636
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.36±0.20(Predicted)
• CAS DataBase Reference: 2H-Imidazo[4,5-b]pyridin-2-one,6-bromo-1,3-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Imidazo[4,5-b]pyridin-2-one,6-bromo-1,3-dihydro-(148038-83-9)
• EPA Substance Registry System: 2H-Imidazo[4,5-b]pyridin-2-one,6-bromo-1,3-dihydro-(148038-83-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 148038-83-9(Hazardous Substances Data)

Usage

General Description

2H-Imidazo[4,5-b]pyridin-2-one, 6-bromo-1,3-dihydro- is a chemical compound with the formula C8H7BrN2O. It belongs to the family of imidazo[4,5-b]pyridine derivatives, which are commonly used in pharmaceutical research. 2H-Imidazo[4,5-b]pyridin-2-one,6-bromo-1,3-dihydro- is a heterocyclic organic compound with a pyridine ring fused to an imidazole ring, and it contains a bromine substituent at the 6th position. This chemical may have potential pharmacological properties, and its structure makes it a valuable building block for the synthesis of various bioactive compounds. It could be used as a starting material in the development of new drugs targeting specific biological pathways or in the study of their impact on biological systems.

InChI:InChI=1/C6H4BrN3O/c7-3-1-4-5(8-2-3)10-6(11)9-4/h1-2H,(H2,8,9,10,11)

Upstream product

• 38875-53-5 5-bromo-pyridine-2,3-diamine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 74124-79-1 di(succinimido) carbonate 
• 273-21-2 3H-imidazo[4,5-b]pyridine 
• 57-13-6 urea 

Relevant articles and documents

Unexpected Result of Imidazo[4,5-b]pyridine Bromination

-

Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents

A persistent latent reservoir of virus in CD4+ T cells is a major barrier to cure HIV. Activating viral transcription in latently infected cells using small molecules is one strategy being explored to eliminate latency. We previously described the use of a FlpIn.FM HEK293 cellular assay to identify and then optimize the 2-acylaminothiazole class to exhibit modest activation of HIV gene expression. Here, we implement two strategies to further improve the activation of viral gene expression and physicochemical properties of this class. Firstly, we explored rigidification of the central oxy-carbon linker with a variety of saturated heterocycles, and secondly, investigated bioisosteric replacement of the 2-acylaminothiazole moiety. The optimization process afforded lead compounds (74 and 91) from the 2-piperazinyl thiazolyl urea and the imidazopyridine class. The lead compounds from each class demonstrate potent activation of HIV gene expression in the FlpIn.FM HEK293 cellular assay (both with LTR EC50s of 80 nM) and in the Jurkat Latency 10.6 cell model (LTR EC50 220 and 320 nM respectively), but consequently activate gene expression non-specifically in the FlpIn.FM HEK293 cellular assay (CMV EC50 70 and 270 nM respectively) manifesting in cellular cytotoxicity. The lead compounds have potential for further development as novel latency reversing agents.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS

The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial FabI and can be used for the treatment of Staphylococcal infections.